Skip to main
ALXO
ALXO logo

ALXO Stock Forecast & Price Target

ALXO Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

ALX Oncology Holdings Inc. is poised for significant revenue growth, with projections indicating an increase from $45 million in 2032 to $278 million by 2034, showcasing a strong upward trajectory in its financial outlook. The company's strategic decisions have successfully extended its cash runway into the fourth quarter of 2026, allowing for focused investment in its clinically de-risked breast and colorectal cancer programs utilizing the CD47 blocker, evorpacept. This combination of projected revenue growth and extended cash runway highlights the company's potential for sustained development and innovation in the immuno-oncology space.

Bears say

ALX Oncology Holdings Inc reported a net loss of $0.58 per share for 1Q25, which exceeded the consensus estimate of a $0.47 loss per share, reaffirming concerns about the company's financial health amidst a lack of revenue. Furthermore, the decision to discontinue evaluations of its candidate Evo for head and neck squamous cell carcinoma and bladder cancer, due to subpar clinical data, highlights potential challenges in advancing its product pipeline. The FDA's request for a Phase 3 study, citing insufficient data from the Phase 2 ASPEN-06 study for accelerated approval, further compounds the company's negative outlook by indicating potential delays and additional costs in achieving regulatory milestones.

ALXO has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ALX Onconology Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ALX Onconology Holdings Inc (ALXO) Forecast

Analysts have given ALXO a Buy based on their latest research and market trends.

According to 5 analysts, ALXO has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ALX Onconology Holdings Inc (ALXO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.